The patient's condition was effectively treated with a combination of oral trimethoprim/sulfamethoxazole and intravenous caspofungin along with clindamycin. Prompt identification and timely intervention are essential to achieve better outcomes in patients with pralsetinib-induced PJP. Furthermore, it highlights the scenario where patients who have fully recovered from moderate-to-severe pralsetinib-induced PJP may undergo pralsetinib re-administration without requiring alternative treatment options.

P=N/A, N=130, Not yet recruiting, Jessa Hospital

P=N/A, N=1600, Not yet recruiting, Washington University School of Medicine

P3, N=222, Completed, University of Oxford | Recruiting --> Completed | N=463 --> 222

The sensitivity of three common drugs (homoharringtonine, lapatinib, and palbociclib) in LUAD could be evaluated by the CR-relevant risk model. Ultimately, the experimental results confirmed that the expression trends of CDK1 and HLA-DMA in our collected clinical samples were in line with the expression trends in the TCGA-LUAD dataset. In conclusion, a CR-relevant risk model based on CDK1 and HLA-DMA was constructed by using bioinformatics analysis, which might supply a new insight into the improved prognosis of LUAD.

P2/3, N=610, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P=N/A, N=30, Active, not recruiting, University of Liverpool | Trial completion date: Dec 2024 --> Dec 2026

These findings suggest that FOXM1 inhibition could be particularly effective in patients with high KPNA2 expression, offering a novel therapeutic strategy for this specific molecular subtype. Several FOXM1 inhibitors, including thiostrepton and FDI-6, warrant investigation as potential targeted treatments for KPNA2-high HR+HER2- breast cancer patients.

Overall, our results indicate that FOXM1 can serve as a novel target for ICC immunotherapy. By targeting FOXM1, TST exerts "dual anti-tumor" effects and has the potential to become a promising immunotherapy agent for ICC patients.

MLKL inactivation reduces such autophagy and renders the cells sensitive to autophagy inhibitors, such as homoharringtonine. Hence, MLKL inhibition creates a therapeutic vulnerability that could be utilized for CRC treatment.

P3, N=196, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Jan 2025

P1, N=12, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Completed | N=36 --> 12 | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Aug 2024

P2, N=24, Recruiting, University of Southern California | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Dec 2025

Ejaculates were divided into two parts; the first one was assessed in native state while the second one was extended in the Androstar Plus extender containing gentamycin, stored at 5 °C and evaluated following 72 h. Young animals presented with a significantly lower sperm motility (p < 0.01), membrane and acrosome integrity (p < 0.0001), and mitochondrial activity (p < 0.0001) against adult boars...and Escherichia coli continued to be identified in samples collected from adult boars. In conclusion, age contributes to the overall quality of fresh as well as liquid-stored boar semen.

P3, N=100, Suspended, Rush University Medical Center | Trial completion date: Dec 2025 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Dec 2024 --> Dec 2025

P4, N=58, Completed, Inonu University

Gentamicin, isoproterenol, and tumor necrosis factor are repurposing new drugs that target CD44, which plays an important role in the development of AD. Following our model validation using the existing experimental data, our model based on previous experimental reports suggested critical molecules and candidate drugs involved in AD for further investigations in vitro and in vivo.

P4, N=200, Recruiting, Western Galilee Hospital-Nahariya

P3, N=280, Not yet recruiting, Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

The patient underwent an open biopsy of the right femur with irrigation and debridement that was inconclusive, but cultures were positive for methicillin-resistant Staphylococcus aureus (MRSA) and group G hemolytic streptococci that were treated with clindamycin...The patient was diagnosed with chronic recurrent multifocal osteomyelitis (CRMO). He had clinical and laboratory improvement for two years on methotrexate. He was then tried on a short course of steroids and adalimumab for worsening symptoms. Bone biopsy was repeated, and findings were consistent with Gaucher disease (GD), which was confirmed on biochemical testing with low beta-glucosidase activity. He was started on enzyme replacement therapy with clinical and biochemical improvement.

We evaluated whether higher plasma interleukin 6 (IL-6) levels would be associated with more severe negative or depressive symptoms in schizophrenia and explored illness stage utilizing early (BeneMin [Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism], n = 201, 72.8% male) and established (iRELATE [Immune Response & Social Cognition in Schizophrenia], n = 94, 67.3% male) schizophrenia cohorts...All analyses were adjusted for sex, age, and chlorpromazine equivalent dose...Our results indicate that higher plasma IL-6 levels may be differently associated with the severity of depressive and negative symptoms dependent on the illness stage. Future work identifying elevated levels of inflammation in larger samples may allow stratification and personalized intervention by subgroups who are at risk of poor outcomes.

P3, N=876, Recruiting, Nanfang Hospital, Southern Medical University

P=N/A, N=20, Recruiting, Johns Hopkins University | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2026

P=N/A, N=50, Recruiting, University of California, Irvine | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025

P1/2, N=28, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: May 2024 --> Aug 2024

pylori clarithromycin resistance will be determined by molecular method from stool samples...Findings will be disseminated in peer-reviewed journals and scientific meetings to guide future practices. NCT05926804.

P2, N=44, Completed, International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed | Trial completion date: Nov 2029 --> Dec 2024

P2, N=6, Completed, University of Louisville | Active, not recruiting --> Completed | N=36 --> 6

P3, N=8, Enrolling by invitation, Universidad Austral de Chile

P=N/A, N=1000, Completed, Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital Affiliated to To | Recruiting --> Completed

P2, N=200, Active, not recruiting, Prisma Health-Upstate | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P=N/A, N=90, Recruiting, Fayoum University

P=N/A, N=13678, First Affiliated Hospital of Xinjiang Medical University; First Affiliated Hospital of Xinjiang Medical University

P=N/A, N=56, Peking University Stomatological Hospital; Sunstar Co.Ltd

P4, N=40, Recruiting, Tianjin Integrated Traditional Chinese and Western Medicine Hospital (Nankai Hospital, Tianjin); Tianjin Integrated Traditional Chinese and Western Me

P2, N=30, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University

P1, N=284, Fujian Provincial Hospital; Fujian Provincial Hospital

P1, N=25, Completed, Poitiers University Hospital | Recruiting --> Completed | N=16 --> 25

P2, N=0, Withdrawn, Yale University | N=412 --> 0 | Not yet recruiting --> Withdrawn

Artemisinin derivatives (ARTs)-artesunate, artemether, and dihydroartemisinin-are standard malaria treatments and are also known to influence the energy metabolism of parasites, tumors, and immune cells...In contrast, exposure of M2-like macrophages to ARTs induced a metabolic shift towards high anaerobic glycolysis and reduced metabolic activity, suggesting a possible indirect effect of ARTs on the helminth infection. Overall, two-photon NAD(P)H-FLIM proved to be a powerful tool for studying specific metabolic pathways in Ascaris larvae and host macrophages, offering valuable insights into the metabolic mechanisms of drug action on both parasite and host.

Leveraging Connectivity Map resources and high-throughput screening, we identify venetoclax, homoharringtonine, and daunorubicin as potential therapeutic options for RARG-AML. Overall, our findings provide pivotal insights into the molecular mechanisms governed by RARG fusions and enhanced by WT1 loss in AML development and propose a rational therapeutic strategy for RARG-AML.

There was an appreciable difference in the kidney histology of the AAI pre-treated groups compared with the GEN. Hence, the extract has prophylactic potential in managing GEN-induced nephrotoxicity by decreasing the markers of renal function and inflammation and downregulating the markers of apoptosis.